Analytical Data
-
Gene name
TRBV5-4
- Application
-
Alternative Names
T cell receptor beta variable 5-4
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A0C4DH59
-
Expression Region
1-308 aa
-
AA Sequence
MGPGLLCWALLCLLGAGSVETGVTQSPTHLIKTRGQQVTLRCSSQSGHNTVSWYQQALGQGPQFIFQYYREEENGRGNFPPRFSGLQFPNYSSELNVNALELDDSALYLCASSIAREQFFGPGTRLTVLEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSESYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDSRG
-
Molecular Weight
60.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRBV5-4 is a member of the T-cell receptor beta (TCRB) variable gene segment family, which plays a crucial role in the adaptive immune response. Recent studies have indicated that TRBV5-4 is associated with recognition of specific antigens, particularly in the context of viral infections and certain cancers. Its distinct variability provides insights into the diversity of T-cell responses, making it a target of interest in immunology and vaccine development. Researchers investigate the recombinant expression of TRBV5-4 proteins to better understand how T-cells recognize pathogens and to develop targeted therapies. Additionally, TRBV5-4 has shown potential in identifying tumor-specific antigens, suggesting its utility in cancer immunotherapy. The recombinant proteins also serve as critical tools for the development of T-cell receptor therapies, allowing for custom-engineered T-cells that can effectively target malignant cells or enhance immune responses against chronic infections. Overall, the study of TRBV5-4 recombinant proteins is contributing to advances in immunotherapy, providing valuable insights into T-cell functionality and offering avenues for innovative therapeutic strategies.
